Methoxsalen ( DrugBank: Methoxsalen )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
36	表皮水疱症	1
46	悪性関節リウマチ	2
51	全身性強皮症	1
96	クローン病	3

36. 表皮水疱症

臨床試験数 : 160 / 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004359 (ClinicalTrials.gov)	February 1996	18/10/1999	Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita		Epidermolysis Bullosa Acquisita	Drug: methoxsalen	National Center for Research Resources (NCRR)	Northwestern University	Completed	18 Years	N/A	Both	10	Phase 2	NULL

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-001825-69-IT (EUCTR)	04/11/2005	14/12/2005	A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex	A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex	Rheumatoid arthritis MedDRA version: 6.1;Level: PT;Classification code 10039073	Trade Name: UVADEX INN or Proposed INN: Methoxsalen	THERAKOS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	68		Italy
2	NCT00221000 (ClinicalTrials.gov)	August 2003	13/9/2005	Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents	Rheumatoid Arthritis	Drug: Methoxsalen;Procedure: Extracorporeal Photopheresis	Mallinckrodt	NULL	Completed	18 Years	N/A	Both	86	Phase 2	United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa

51. 全身性強皮症

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04986605 (ClinicalTrials.gov)	March 2022	1/6/2021	Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis	The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis	Diffuse Cutaneous Systemic Sclerosis	Other: Extracorporeal Photopheresis (ECP) with Methoxsalen	Lawson Health Research Institute	Mallinckrodt	Not yet recruiting	18 Years	N/A	All	15	Phase 2	Canada

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-002693-37-DE (EUCTR)	14/03/2005	06/01/2005	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - CD-2	Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents MedDRA version: 7.1;Level: LLT;Classification code 10011401	Trade Name: UVADEX INN or Proposed INN: methoxsalen	Therakos	NULL	Not Recruiting			Female: yes Male: yes	25		Germany
2	EUCTR2004-002693-37-AT (EUCTR)	10/12/2004	05/11/2004	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/A	A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSANTS AND/OR ANTI-TNF AGENTS - N/A	Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents MedDRA version: 7.1;Level: LLT;Classification code 10011401	Trade Name: UVADEX INN or Proposed INN: methoxsalen	Therakos	NULL	Not Recruiting			Female: yes Male: yes	25		Austria;Germany
3	NCT00221026 (ClinicalTrials.gov)	December 2004	13/9/2005	Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease	A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents	Crohn's Disease	Drug: Methoxsalen +ECP;Procedure: Extracorporeal Photopheresis	Mallinckrodt	ICON plc	Completed	18 Years	N/A	Both	25	Phase 2	United States;Austria;Belgium;Germany

先頭へ